Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Segment Highlights
IDXX logo

IDEXX Revenue Surges 13% on Recurring Diagnostics Strength

IDXX10-QFiling Date: 11/3/2025
IDEXX Laboratories, Inc.
Description

What this story covers

IDEXX Laboratories' Q3 2025 10-Q shows 13% revenue growth to $1.105B, driven by 11.7% organic gains in companion animal diagnostics. Net income up 18% to $275M, with strong cash flow of $826M YTD. Diversified segments and hedges manage risks, supporting strategic investments and repurchases.

Story snapshot

CompanyIDEXX Laboratories, Inc.
TickerIDXX
VariantStandard detailed
Duration13:33
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000874716-25-000165

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in